Our leadership team is comprised of pharmaceutical industry veterans with unparalleled and extensive experience in advanced Parkinson's disease and proven track records in the discovery, development and commercialization of groundbreaking therapies to improve patient lives. Collectively, the team has a diverse background and broad skill set having successfully led numerous product launches, domestically and internationally, within the pharmaceutical, biotechnology and medical device industries for both small and large public and private companies.
Chief Executive Officer and Board Member
Patrick Shea is the chief executive officer at Intrance Medical Systems, Inc. In this role, he is responsible for building the company’s infrastructure to develop and commercialize its novel treatment for advanced Parkinson’s disease. He is also a member of the board. Mr. Shea has proven experience in leading and growing commercial organizations within the pharmaceutical and biotechnology industry across a diverse set of companies, markets and therapeutic areas. Additionally, he has successfully led a number of specialty product launches and has significant strategic business development expertise.
In his most recent position, Mr. Shea served as senior vice president of commercial at Antares Pharmaceuticals. Prior, he served in chief commercial officer roles at Eaglet Corporation and Clarus Therapeutics. Mr. Shea has also held executive leadership positions at CSL Behring, Astellas Pharmaceuticals U.S. and commercial assignments of increasing responsibility at Ligand Pharmaceutical and Boehringer Ingelheim Pharmaceuticals.
He holds a bachelor of arts degree from Alfred University.
Interim Chief Medical Officer and Board Member
Fredrik Buch, M.D., Ph.D.
Fredrik Buch, M.D., Ph.D., joined Intrance Medical Systems, Inc. as director of the board in 2018. He has significant experience in both clinical work and drug development in the pharmaceutical sector as well as profound experience in company start-ups, fund investing and financing.
He is a director of a number of life science companies in Sweden, including Lantmännen Medical AB, Cytovac AB and Acarix AB and serves as chairman at Huvudsta Vårdcentral AB, Tridentify AB and Citadellet AB.
In addition, Dr. Buch has served as head of SEB Healthcare Funds and partner at HealthCap and has been acting as a financial advisor to start-up companies, raising capital and serving on various boards in Sweden and abroad since 2000. He has served on more than 20 boards prior to joining Intrance. During his career, he has held several clinical research positions at leading pharmaceutical and biotechnology companies, including Bristol Myers Squibb, Hoechst, Pharmacia and Pharmacia & Upjohn, and has authored more than 20 scientific publications.
Dr. Buch is an orthopedic surgeon and scientist by training and holds an M.D. in medicine and a Ph.D. from the University of Gothenburg.
Vice President of Business Development
Ashley Prange is vice president of business development at Intrance Medical Systems, Inc. In this role, she is responsible for building and implementing the company’s strategic partnering initiatives for the U.S., Japan, Taiwan, Canada, and South America.
Ms. Prange is a target-driven successful professional with strong experience in sales, business development, and marketing. She brings to Intrance both commercial and business development leadership experience across multiple therapeutic areas in the specialty pharmaceutical space, including neurology and Central Nervous System (CNS) diseases.
Most recently, she served as director of business development at Azurity Pharmaceuticals, where she led the licensing and the product acquisition team responsible for identifying strategic business opportunities. Prior to Azurity, she was director of business development at Arbor Pharmaceuticals (acquired by Azurity in 2021) working closely with the board and management team to spearhead high-priority strategic corporate transactions. She has a proven track-record sourcing, structuring, and negotiating partnerships to optimize mutual value.
Ms. Prange is a former Ladies Professional Golf Association (LPGA) professional and graduate of the University of North Carolina Chapel Hill, where she earned a bachelor’s degree in journalism specializing in advertising and sports marketing.
Vice President of Clinical Development
Krai Chatamra, B.Sc., Ph.D.
Krai Chatamra is vice president of clinical development at Intrance Medical Systems, Inc. He has over 20 years of international drug development experience gained through leadership roles at small and large biopharmaceutical companies, including Theravance, Lundbeck, AbbVie, Abbott, Pfizer and Merck.
Dr. Chatamra led the successful clinical development program for levodopa-carbidopa intestinal gel (Duopa®/Duodopa®) for advanced Parkinson’s disease, which is now approved in more than 70 countries, including the U.S. and Japan. Over the course of his career, Dr. Chatamra has been responsible for developing and advancing multiple therapeutic indications within neuroscience, oncology, cardiovascular and respiratory medicine. Dr. Chatamra’s clinical research has been widely published in numerous scientific journals, including articles on advanced Parkinson’s disease and real-world evidence for intra-duodenal infusion of levodopa.
He holds a BSc (Hons) in physiology and a Ph.D. from the University of Bristol in the United Kingdom.
Co-Founder and Chairman of the Board
Ulf Rosén is co-founder and chairman of Intrance Medical Systems, Inc. and Intrance Holding AB.
Mr. Rosén has over 35 years of proven experience in the pharmaceutical and medical technology industry including more than 20 years at start-up and early-stage companies as investor, CEO and member of the board/chairman. During his career, he has been directly involved in several strategic investments and M&A activities and has extensive experience in Parkinson’s disease. Mr. Rosen was instrumental in pioneering the development of levodopa-carbidopa intestinal gel commercialized in the EU member states as Duodopa®. Such success led to its acquisition by Solvay Phamaceuticals and Abbott/AbbVie where Duopa® was subsequently approved in the United States.
Mr. Rosén was co-founder and CEO of Lobsor Pharmaceuticals which was acquired by STADA/Britannia in September 2020. Previously, he held senior management positions in larger organizations as CEO for Pharmacia & Upjohn Norway as well as executive vice president of Fresenius Kabi Global Nutrition Division. He currently serves as an independent board member of Acarix AB (listed at Nasdaq FN).
He holds a BSc from Mälardalen University (Sweden), and master’s degrees in business administration and general management from IHM Business School and executive financial management from INSEAD.
Roger Bolsöy, M.Sc.
Roger Bolsöy is co-founder of Intrance Medical Systems, Inc. and acts as a strategic and operational advisor for the company. Mr. Bolsöy is the key inventor of the triple-drug combination of carbidopa, entacapone and levodopa. He has extensive experience in the discovery, development and commercialization of pharmaceutical products and medical devices with a particular focus on advanced Parkinson’s disease.
His career spans more than 20 years of international life science experience where he held positions of increasing responsibility at leading pharmaceutical and medical technology companies, including AbbVie, Abbott, Solvay and NeoPharma. Mr. Bolsöy was directly involved in taking levodopa-carbidopa intestinal gel (Duopa®/Duodopa®) for the treatment of advanced Parkinson’s disease from its development phase through to its successful EU launch. In addition, he also held various senior management positions in manufacturing, development, global marketing and geographical expansion.
He holds a master’s in science in technology and chemistry from the University of Uppsala in Sweden.
*The product, Duopa® in U.S./Duodopa® in Europe, mentioned above is a registered trademark of AbbVie.